U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

57

OSAKA, Japan–(BUSINESS WIRE)–FDA has accepted for review a BLA for a subcutaneous formulation of Entyvio for maintenance therapy in adults with moderately to severely active UC http://www.businesswire.com/news/home/20190509005450/en/U.S.-Food-Drug-Administration-Accepts-Takeda%E2%80%99s-Biologics/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==